About Etcembly
Etcembly is a company based in Harwell (United Kingdom) founded in 2020 by Jacob Hurst and Michelle Teng. Etcembly has raised $12.66 million across 4 funding rounds. Etcembly offers products and services including EMLy and Long Term Survivor Study. Etcembly operates in a competitive market with competitors including Archon Bio, SQALE, Neuromathix, Sprectroo and Protains, among others.
- Headquarter Harwell, United Kingdom
- Founders Jacob Hurst, Michelle Teng
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Etcembly Ltd
- Date of Incorporation 19 Jun, 2019
- Jurisdiction DIDCOT, OXFORDSHIRE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.66 M (USD)
in 4 rounds
-
Latest Funding Round
$4.53 M (USD), Series A
Jun 11, 2023
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Etcembly
Etcembly offers a comprehensive portfolio of products and services, including EMLy and Long Term Survivor Study.
AI tool for decoding immune repertoires and designing TCRs.
Program to analyze cancer survivors' immune data for new targets.
Funding Insights of Etcembly
Etcembly has successfully raised a total of $12.66M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.53 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Etcembly
Investment portfolio details for Etcembly
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Etcembly
Detailed financials for Etcembly
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Etcembly Comparisons
Peer comparison for Etcembly
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Etcembly
Etcembly operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Archon Bio, SQALE, Neuromathix, Sprectroo and Protains, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of computational platform to develop protein therapeutics
|
|
| Locked | Locked | Locked |
Provides bioprocess optimization services for microalgae and precision fermentation companies.
|
|
| Locked | Locked | Locked |
Offers decision support software for personalized healthcare models based on patient data.
|
|
| Locked | Locked | Locked |
Sprectroo is an AI-driven platform for drug derivatization and repurposing.
|
|
| Locked | Locked | Locked |
AI-driven platform for drug discovery using algorithms and computing resources.
|
Detailed competitors of Etcembly
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Etcembly
Complete news archive for Etcembly
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Etcembly
Etcembly was founded in 2020.
Etcembly is headquartered in Harwell, United Kingdom. It is registered at Harwell, Oxfordshire, United Kingdom.
Michelle Teng is the current CEO of Etcembly. They have also founded this company.
Etcembly is a funded company, having raised a total of $12.66M across 4 funding rounds to date.
Etcembly was founded in 2020 and is based in Harwell, United Kingdom. Operations focus on the biotechnology sector, where an AI-based platform is developed to engineer T cell receptors for cancer immunotherapy. Machine learning techniques are employed within the platform to create high-affinity TCRs, enabling treatments with defined speed and precision. Services target advancements in personalized cancer therapies through computational design.
Etcembly's top competitors include Archon Bio, SQALE and Neuromathix.
Etcembly offers EMLy and Long Term Survivor Study.